Copyright
©The Author(s) 2020.
World J Gastroenterol. Jul 14, 2020; 26(26): 3834-3850
Published online Jul 14, 2020. doi: 10.3748/wjg.v26.i26.3834
Published online Jul 14, 2020. doi: 10.3748/wjg.v26.i26.3834
Table 3 Demographic and clinical characteristics of patients with low-grade dysplasia detected on visible gastric lesions or randomly and without low-grade dysplasia, before and after Helicobacter pylori eradication
Parameters | With LGD (n = 28) | Without LGD (n = 57) | P value |
Age, mean (SD), yr | 60.9 (8.2) | 53.7 (13.4) | 0.01a |
Gender, n (%) | |||
Female | 15 (53.6) | 38 (66.7) | 0.24 |
BMI, mean (SD), kg/m2 | 25 (2.4) | 25 (2.3) | 1.0 |
Alcohol users (12-24 g/dL/die), n (%) | 15 (53.6) | 12 (21.1) | 0.002b |
Previous smokers, n (%) | 10 (35.7) | 2 (3.5) | < 0.0001c |
Family history of gastric cancer, n (%) | 4 (14.3) | 0 | 0.001c |
Family history of other cancer, n (%) | 6 (21.4) | 3 (5.3) | 0.001c |
Autoimmune comorbidity | |||
Autoimmune atrophic gastritis | 8 (28.6) | 4 (7) | 0.02c |
Autoimmune thyroiditis | 3 (10.7) | 3 (5.3) | 0.39 |
A. thyroiditis + vitiligo | 1 (3.6) | 0 | 0.33 |
A. thyroiditis + Crohn’s disease | 1 (3.6) | 0 | 0.33 |
A. thyroiditis + Sjögren syndrome | 0 | 1 (1.7) | 1.0 |
Sjögren syndrome | 0 | 1 (1.7) | 1.0 |
Type-1/2 diabetes mellitus | 1 (3.6) | 2 (3.5) | 1.0 |
Skin psoriasis | 1 (3.6) | 0 | 0.33 |
Rheumatoid arthritis | 0 | 1 (1.7) | 1.0 |
APCA and/or AIF antibody positivity | 8 (28.6) | 4 (7) | 0.02c |
H. pylori eradication scheme, n (%) | |||
Quadruple1 | 17 (60.7) | 36 (63.2) | 0.82 |
Modified triple2 | 9 (32.1) | 19 (33.3) | 0.91 |
Triple3 | 1 (3.6) | 2 (3.5) | 1.0 |
Sequential4 | 1 (3.6) | 0 | 0.33 |
H. pylori eradication cycles, n (%) | |||
One cycle | 22 (78.6) | 46 (86) | 0.82 |
Two cycles | 6 (21.4) | 8 (14) | 0.82 |
OLGA scale before5 | |||
Stage 0 | 0 | 4 (7) | 0.3 |
Stage 1-2 | 8 (28.6) | 48 (84.2) | < 0.0001b |
Stage 3-4 | 20 (71.4) | 5 (8.8) | < 0.0001c |
OLGA scale after6 | |||
Stage 0 | 0 | 4 (7) | 0.3 |
Stage 1-2 | 7 (25) | 44 (77.2) | < 0.0001b |
Stage 3-4 | 21 (75) | 9 (15.8) | < 0.0001b |
OLGIM scale before | |||
Stage 0 | 0 | 40 (70.1) | < 0.0001c |
Stage 1-2 | 12 (42.8) | 16 (28.1) | 0.17 |
Stage 3-4 | 16 (57.1) | 1 (1.8) | < 0.0001c |
OLGIM scale after | |||
Stage 0 | 0 | 29 (50.9) | < 0.0001c |
Stage 1-2 | 7 (25) | 24 (42.1) | 0.12 |
Stage 3-4 | 21 (75) | 4 (7) | < 0.0001c |
Gastritis at histology before, n (%) | |||
Quiescent | 0 | 0 | 1.0 |
Mild | 3 (10.7) | 16 (28.1) | 0.10 |
Moderate-severe | 25 (89.3) | 41 (71.9) | 0.10 |
Gastritis at histology after, n (%) | |||
Quiescent | 26 (92.9) | 55 (96.5) | 0.59 |
Mild | 2 (7.1) | 2 (3.5) | 0.50 |
Moderate-severe | 0 | 0 | 1.0 |
MALT hyperplasia before, n (%) | |||
Absent | 10 (35.7) | 36 (63.2) | 0.02b |
Mild | 10 (35.7) | 15 (26.3) | 0.37 |
Moderate | 6 (21.4) | 5 (8.8) | 0.17 |
Severe | 2 (7.2) | 1 (1.8) | 0.25 |
MALT hyperplasia after, n (%) | |||
Absent | 10 (35.7) | 36 (63.2) | 0.02b |
Mild | 18 (64.3) | 21 (36.8) | 0.02b |
Moderate | 0 | 0 | 1.0 |
Severe | 0 | 0 | 1.0 |
- Citation: Panarese A, Galatola G, Armentano R, Pimentel-Nunes P, Ierardi E, Caruso ML, Pesce F, Lenti MV, Palmitessa V, Coletta S, Shahini E. Helicobacter pylori-induced inflammation masks the underlying presence of low-grade dysplasia on gastric lesions. World J Gastroenterol 2020; 26(26): 3834-3850
- URL: https://www.wjgnet.com/1007-9327/full/v26/i26/3834.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i26.3834